Fasting Study of Mercaptopurine 50 mg and Purinethol® Tablets 50 mg
Status:
Completed
Trial end date:
2003-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to investigate the bioequivalence of Mylan's mercaptopurine
50 mg tablets to Gate's Purinethol® 50 mg tablets following a single, oral 50 mg (1 x 50 mg)
dose administered under fasting conditions.